Stenobird

Episode

Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho

Podcast
Business Of Biotech
Published
Jun 22, 2026
Duration seconds
3313
Processing state
not_requested
Canonical source
https://www.buzzsprout.com/1011661/episodes/19360445-keeping-an-early-stage-cell-therapy-biotech-in-the-black-with-in8bio-s-william-ho.mp3
Audio
https://www.buzzsprout.com/1011661/episodes/19360445-keeping-an-early-stage-cell-therapy-biotech-in-the-black-with-in8bio-s-william-ho.mp3
JSON
/v1/public/podcasts/business-of-biotech-123501/episodes/keeping-an-early-stage-cell-therapy-biotech-in-the-black-with-in8bio-s-william-ho
Markdown
/podcast/business-of-biotech-123501/keeping-an-early-stage-cell-therapy-biotech-in-the-black-with-in8bio-s-william-ho.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/keeping-an-early-stage-cell-therapy-biotech-in-the-black-with-in8bio-s-william-ho/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/business-of-biotech-123501/keeping-an-early-stage-cell-therapy-biotech-in-the-black-with-in8bio-s-william-ho.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch. Access this and hundreds of episodes of the Business of Biotech videocas...